Harry J. M. Groen, MD, PhD; University Medical Center Groningen 5Live #ASCO20
4:19
Key insights on Capmatinib in patients with METex14-mutated or high-level MET-amplified advanced non–small-cell lung cancer (NSCLC): results from cohort 6 of the phase 2 GEOMETRY mono-1 study.
Key insights on Capmatinib in patients with METex14-mutated or high-level MET-amplified advanced non–small-cell lung cancer (NSCLC): results from cohort 6 of the phase 2 GEOMETRY mono-1 study.
Non Small Cell Lung Cancer Similar Videos
-
Narjust Duma, MD; University of Wisconsin-Madison, University of Wisconsin Carbone Cancer Center; 5Live; #IASLC21
5:10
-
Vivek Subbiah, MD The University of Texas MD Anderson Cancer Center 5Live #ASCO20
6:47
Key Insights on Intracranial activity of selpercatinib (LOXO-292) in RET fusion-positive non-small cell lung cancer (NSCLC) patients on the LIBRETTO-001 trial.
-
Andreas N. Saltos, MD; Moffitt Cancer Center; 5Live; #IASLC21
13:27